TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Popliteal Plexus Block for Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female at least 50 years of age at screening~* Scheduled to undergo primary total knee arthroplasty in spinal anesthesia~* Normal sensory function at the lateral part of the thigh and lower leg~* American Society of Anesthesiologists (ASA) physical status 1, 2, or 3~* Able to provide informed consent~Exclusion Criteria:~* Unable to cooperate and follow the study protocol~* Communication problems~* Allergic towards any medical product administered in the study~* Diabetes requiring medical treatment~* Pregnancy (a pregnancy test will be conducted on all women of childbearing potential prior to inclusion in the study. A positive test result will result in exclusion from the study)~* Preoperative opioid treatment (dosed \> once daily)

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Active Popliteal Plexus Block (Type: ACTIVE_COMPARATOR): 10 ml Bupivacaine-Epinephrine 0.5%-1:200,000 Injectable Solution
- Placebo Popliteal Plexus Block (Type: PLACEBO_COMPARATOR): 10 ml Sodium Chloride 0.9 %

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Combined Spinal Epidural Urinary Retention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Nulliparous~* Term (≥37 week gestation)~* Healthy~* ASA class 1-2~* Who are being induced for labor who request labor analgesia and who successfully receive standard combined spinal epidural analgesia (verbal rating score for pain ≤ 1 after 10 min)~Exclusion Criteria:~* Women with ASA 3 or greater~* BMI ≥40 kg/m2~* Prior history of urge or stress incontinence or urinary retention before pregnancy~* Women with a history of nephrolithiasis~* Chronic urinary tract infections~* Women whose post-void residual volume as assessed by ultrasonography is found to be \>100ml before epidural placement will be excluded.~* Women with an absolute or relative contraindication to the usual combined spinal epidural technique~* Failed analgesia will be excluded~* Women for whom the anesthesiologist selects an analgesic technique other than combined spinal epidural technique or fail to obtain CSF for CSE will be excluded~* Women with fetal heart rate decelerations before request for analgesia will be excluded due to increased risk of cesarean delivery.~* Women who experience inadequate labor analgesia due to nonfunctioning epidural catheter necessitating epidural replacement will be included but noted as a protocol violation.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Foley catheter (Type: PLACEBO_COMPARATOR): Control group will have a Foley catheter placed after the CSE is performed as is the usual practice at this institution.
- No Foley Catheter (Type: EXPERIMENTAL): Spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Fit of the iTotal Versus Standard Total Knee Implants

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who are scheduled for a standard total knee replacement~* Patient who are scheduled for patient-specific total knee replacement (iTotal)~* Patient age \> 18 years~Exclusion Criteria:~* Patients who do not receive a total knee replacement~* Unwilling or unable to comply with study requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phase I (Type: None): A series of 50 consecutive primary iTotal patients will be compared to assess the fit of the tibial tray intra-operatively. These patients will have a series of tibial templates from Standard TKR implant sets trialed on the operative knee. Each template will be optimally sized and positioned based on the surgeon's judgment. Implant fit data (overhang and underhang) on the tibia for all templates will be taken from intra-operative measurements
- Phase II (Type: None): The Phase I (50 consecutive primary iTotal patients) will also have implant fit data assessed for the femur. After final implantation is complete measurement will be assessed and recorded. A series of 25 primary knees that are scheduled for Standard TKR implants will then undergo the same measurements of the femur.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Non-Invasive, Real-Time Technology for Diagnosis of Cervical Tissue

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with abnormal Pap smears who are referred for colposcopy.~Exclusion criteria include:~* Anyone of the male sex since this study focuses on cervical cell abnormalities~* Any woman who has had a hysterectomy, LEEP, or chemotherapy.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Detection of miRNAs in HPA Axis Function in Healthy Subjects

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults age ≥ 18~Exclusion Criteria:~* Pregnancy~* Presence of a disease that affects HPA axis function~* Current use of medications that affect cortisol secretion, such as opioid pain medication, anti-fungal agents, anti-epileptic agents, and glucocorticoids, including hydrocortisone, prednisone, dexamethasone, steroid-containing inhalers, and steroid injected into the joints~* History of adverse event related to use of glucocorticoids

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Dexamthesone (Type: EXPERIMENTAL): Single arm study in which all healthy controls will receive 1 mg of dexamethasone intravenous (IV) injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: MODULA-Study: Modul 10: Benefit of CRT-Therapy in CRT-Patients With QRS-Complex of 120 - 150 Ms

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with cardiac resynchronization therapy with a defibrillator (CRT-D) or cardiac resynchronization therapy pacemakers (CRT-P) system~* New York Heart Association (NYHA) III~* Ejection fraction (EF) below 35%~* Optimised medical therapy~* QRS-complex above 120 ms~Exclusion Criteria:~* Patients with CRT-P and atrial fibrillation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- QRS 120-150 ms (Type: None): Subjects with a QRS width between 120-150 ms
- QRS >150 ms (Type: None): Subjects with a QRS width \>150 ms

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: TMQLB Versus TPVB for Acute Pain and Quality of Recovery After Laparoscopic Renal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 17\~80 years of age;~* American Society of Anesthesiologists physical status I-III;~* undergoing laparoscopic nephrectomy.~Exclusion Criteria:~* have a known allergy to the anesthetics being used;~* infection at injection site~* coagulopathy or history of anticoagulants use~* chronic analgesics consumption or history of substance abuse~* inability to properly describe postoperative pain or recovery to investigators (e.g., language barrier, neuropsychiatric disorder).

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- TMQLB group 1 (Type: EXPERIMENTAL): 0.4ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
- TMQLB group 2 (Type: EXPERIMENTAL): 0.6ml/kg ropivacaine is injected into the interfascial plane between the psoas major and quadratus lumborum muscle using TMQLB approach.
- TPVB group (Type: ACTIVE_COMPARATOR): 0.4ml/kg ropivacaine is injected into the thoracic paravertebral space (T10) using TPVB approach.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: High Flow Nasal Cannula Use in Infants With Bronchiolitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admission to pediatric ward due to a presumed viral bronchiolitis~* Need of oxygen therapy (oxygen saturation \< 92%)~Exclusion Criteria:~* Pertussis~* Needs intubation or CPAP on admission~* Severe congenital heart defect~* Down's syndrome

- Gender: ALL
- Minimum Age: None
- Maximum Age: 6 Months
- Healthy Volunteers: f

Study Arms:
- Usual oxygen therapy (Type: ACTIVE_COMPARATOR): Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
- High flow oxygen therapy (Type: EXPERIMENTAL): High flow nasal cannula oxygen therapy with Airvo (TM, Fisher \& Paykel Healthcare) device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Change in Thrombin Generation Potential and Thromboelastography During the Menstrual Cycle

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Females of reproductive age with regular menstrual cycles and a diagnosis of von Willebrand disease according to the International Society of Thrombosis and Hemostasis diagnostic criteria.~Exclusion Criteria:~* Females who are pregnant, or have a history of endocrinopathy or hormone imbalance~* History of hysterectomy or bilateral oophorectomy~* History of ovarian or uterine cancer~* Use of intrauterine device~* Use of antifibrinolytic therapy, hemostatic agents, or anti-platelet agents.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Lamictal in the Treatment of Post-Herpetic Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All patients will be over the age of 18,~* Need to have a diagnosis of Post-Herpetic Neuralgia,~* Minimum of 4 on the Likert Pain Scale,~* If currently taking TCA and/or Gabapentin, need to have been on stable dose for minimum of 4 weeks~Exclusion Criteria:~* Currently on any antiepileptic drugs (AED), except for Gabapentin.~* Currently taking opioid or unwilling to washout prior to the study,~* Pregnant and lactating,~* Have active severe systemic disease,~* History of Stevens-Johnson syndrome or TEN,~* Clinically significant abnormal lab values,~* Known drug allergy to Lamictal,~* Patients on Fibrates (Tricor and Lopid),~* History of major psychiatric disturbance and substance abuse.~* Valproate due to increase chances of severe rash,~* Lidocaine Patch,~* Use of hormonal contraceptives (birth control pills, patch, ring, injection)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vaccination Response in Individual Monozygotic Twins

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Volunteers are eligible to participate in this study if both they and their twin sibling have agreed to participate. If after their enrollment in the study, one of the twin siblings decides to withdraw, then:~1. If one sibling withdraws during Year 1, the other sibling will be allowed to continue their participation in the study and to complete the current study Year. However they will not be included in the randomly selected applicants that will continue participation in Year 2 of the study.~2. If one sibling withdraws duringYear2, the other sibling will be able to conclude Year2 study activities. -~Exclusion Criteria:~1. Volunteer is under18.~2. Presence of any medical conditions that the study investigators believe will affect participation in the study or its results.~3. Presence of a mental incapacity and/or cognitive impairment that would prevent a subject from adequately understanding, or cooperating with, the study protocol.~4. Volunteers with any severe allergies (life-threatening) or that have ever had a life-threatening allergic reaction after a dose of flu vaccine, or have a known severe allergy to any part of this vaccine, will be advised not to participate.~5. If a potential subject has ever had Guillain-Barré Syndrome (a severe paralyzing illness, also called GBS), they will be advised not to get the influenza vaccine and be excluded from this study.~   * For female participants If they are already enrolled and become pregnant during this study, the investigators will temporarily withdraw them from the study from the day they become pregnant. If they would like to stay in the study, the investigators may continue their participation after their delivery.~  * If participants are not feeling well on the scheduled day of vaccination the investigators will suggest that they postpone the vaccination until they feel better. If they agree, the vaccination will be re-scheduled for a later date.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Asthma Discordant Monozygotic Twins (Type: None): This is a group where one of the monozygotic twins has asthma and the other is non-asthmatic. Influenza Vaccination will be performed for both cohorts.
- Non-Asthma Concordant Monozygotic Twins (Type: None): This is a group where both of the monozygotic twins are non-asthmatic. Influenza Vaccination will be performed for both cohorts.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with relapsed or refractory Mantle Cell lymphoma with measurable disease.~* Age \> 18 years old~* Expected survival \>/= 3 months~* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 at initiation of study (Appendix I).~* Laboratory tests meet the levels specified in the protocol~Exclusion Criteria:~* Patients must not have received chemotherapy, radiation or surgical resection of malignancy within 3 weeks of study initiation. However, if they have received nitrosurea or mitomycin C then they should not be enrolled in the study until 6 weeks after therapy was last received.~* No limitations to number of prior therapies~* No prior radioimmunotherapy (RIT)~* Prior bortezomib is allowed~* Patient must be fully recovered from all toxicities associated with prior surgery, radiation treatment, chemotherapy or immunotherapy.~* No active, serious infection or medical or psychiatric illness likely to interfere with participation in this clinic trial~* No known HIV infection~* No active central nervous system (CNS) involvement~* Bone Marrow Involvement \>/= 25% within 30 days of initiation of study treatment~* Pregnant or breast feeding~* No patients who have received Granulocyte colony-stimulating factor (G-CSF) or Granulocyte macrophage colony-stimulating factor (GM-CSF) within the 14 days prior to initiating protocol~* No patient who has had major surgery within the four weeks prior to initiating protocol therapy~* No patients with pleural effusion or significant ascites

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zevalin + Velcade (Type: EXPERIMENTAL): Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan~Other Names:~Rituxan Velcade Zevalin~Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4 millicurie (mCi)/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Statins for the Early Treatment of Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Initial presentation to the Emergency Department or University of Chicago MD office/Dialysis Center for current hospital admission~* Sepsis (ACCP/SCCM criteria)~  1. Clinically suspected infection as per the treating physician or confirmed infection~ 2. 2 or more of the following: Temperature 38ºC (100.4ºF)or 36ºC (96.8ºF), Heart rate (HR) \> 90/min, Respiratory rate (RR) \> 20/min or PaCO2 \< 32 mmHg, White blood cell count \> 12,000/mm3 or \< 4000/m3 or \> 10%immature neutrophils~* Initiation of antibiotics by treating physician for sepsis~* Hospitalized from the Emergency Department or University of Chicago MD office/Dialysis Center to an inpatient medical service (intensive care unit (ICU)or non-ICU service) OR admission to the medical ICU (MICU) from a non-ICU inpatient medical floor.~* Assent of the primary treating physician at the time of enrollment.~* The meeting of SIRS criteria is due to an infection as per the treating physician.~Exclusion Criteria:~* Pregnancy~* ALT \>3 times above the upper limit of normal~* Elevated creatine phosphokinase (CPK) (\>3 times the upper limit of normal)~* Concurrent treatment with any of the following drugs: daptomycin, fenofibrate, ketoconazole,triaconazole, amiodarone, clarithromycin, cyclosporine, erythromycin,nefazodone, niacin, protease inhibitors, telithromycin, verapamil,danazol, gemfibrozil~* History of allergy or intolerance to statins~* Greater than 16 hours after meeting inclusion criteria~* Use of 1 more doses of statins in the previous 4 weeks~* Clinical indication for treatment with statin during hospital admission (per treating physician)~* Sufficiently poor prognosis prior to enrollment that treating physicians have elected to employ comfort care or plan to discharge to hospice~* Transfer from surgical service to medical service~* Needing transfusion for either active bleeding or severe hemolysis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Simvastatin 80 mg once daily PO (or via NG or G-tube)
- 2 (Type: PLACEBO_COMPARATOR): Identical-appearing placebo PO (or via NG or G-tube)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues